Top Markets
Coin of the day
Pacific Edge Limited Pacific Edge Limited

Pacific Edge Limited

PEB
주식 순위 #18668
Based in Dunedin, New Zealand, Pacific Edge Limited, established in 2001,... Based in Dunedin, New Zealand, Pacific Edge Limited, established in 2001, operates as a cancer diagnostics firm. The company's core mission involves the research, development, and commercialization of advanced diagnostic and prognostic tools aimed at the early identification and ongoing management of various cancers. Its diagnostic solutions are accessible in New Zealand, the United States, Australia, and Singapore, with operations structured across Commercial and Research segments. A key offering is the Cxbladder suite, a collection of genomic urine tests specifically designed for detecting and managing bladder cancer. Within this suite, Cxbladder Resolve aids in identifying patients likely to present with more aggressive or advanced bladder cancer. Cxbladder Triage helps pinpoint individuals with haematuria who exhibit a low probability of bladder cancer, while Cxbladder Detect offers a non-invasive method for identifying bladder and other urinary tract cancers. Furthermore, Cxbladder Monitor facilitates continuous surveillance for disease recurrence in bladder cancer patients. Beyond its focus on bladder cancer, Pacific Edge is actively developing additional diagnostic innovations. These include Cxcolorectal, a prognostic gene signature for assessing outcomes in patients diagnosed with stage II or stage III colorectal cancers, alongside pipeline products targeting gastric, endometrial cancers, and melanoma.
주가
$0.15360289
시가총액
$190.75M
변동 (1일)
6.25%
변동 (1년)
94.11%
국가
NZ
거래 Pacific Edge Limited (PEB)

카테고리

Pacific Edge Limited (PEB)의 배당 수익률 기록
Pacific Edge Limited (주식 심볼: PEB)의 배당 수익률 (TTM)은 2026 기준으로 0입니다.
지난 5년 평균 배당 수익률: 0.00%
Pacific Edge Limited (PEB)의 배당 수익률 기록: 2026 ~ 2026
연도별 말 기준 배당 수익률 (TTM)
연도 배당 수익률 변화
제공된 날짜에 대한 데이터가 충분하지 않습니다.
유사 기업 또는 경쟁사의 배당 수익률 (TTM)